EWTX earnings analysis
What we found in EWTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Edgewise Therapeutics continues to incur significant losses, reporting a net loss of $49.0 million for Q1 2026 compared to $40.8 million in Q1 2025. Operating expenses have increased by 17.7% year-over-year, driven by higher research and development costs. The company expects to maintain its current cash reserves of $499.6 million for at least the next 12 months to support ongoing development activities and clinical trials.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Rising Net Losses
- Net loss increased to $49.0 million in Q1 2026 from $40.8 million in Q1 2025.
- Significant Cash Position
- As of March 31, 2026, the company holds $499.6 million in cash, cash equivalents, and marketable securities.
- Increased R&D Spending
- Research and development expenses rose to $42.7 million from $36.8 million year-over-year, reflecting a 14.1% increase.
- Interest Income Stable
- Interest income was $5.1 million for Q1 2026, slightly down from $5.2 million in Q1 2025.
- Continued Clinical Trials
- The lead product, sevasemten, remains in multiple late-stage clinical trials as per ongoing development plans.
- Potential for Capital Raises
- Management has indicated the plan to engage in additional equity offerings for funding, leaning on the $175 million available through the ATM program.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Widening Operational Losses
- Company continues pre-revenue status, with ongoing losses signaling potential unsustainable cash burn.
- Dependence on Third-Party Collaborators
- Clinical trials are conducted via third-party CROs which may not perform satisfactorily, indicating execution risk.
- Regulatory and Market Risks
- Uncertainties in obtaining regulatory approvals for therapies could prolong development timelines and affect revenue generation.
What they said about what is next.
Management expects to maintain sufficient funding through current resources but is open to future equity offerings.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Edgewise positions itself as a muscle‑focused precision medicines company leveraging a proprietary drug discovery platform to advance small‑molecule sarcomere modulators. The company’s lead program, sevasemten, is in…
- 10-Q · November 6, 2025
- Edgewise reported a Q3 2025 net loss of $40,666 (EPS -$0.39), wider than Q3 2024 net loss of $34,129 (EPS -$0.36) driven by higher R&D and G&A. Cash and marketable securities totaled $563.3 million as of September 30,…
- 10-Q · August 7, 2025
- Edgewise remains pre-revenue and reported a net loss of $36,115,000 for the three months ended June 30, 2025 (EPS -$0.34), compared with a net loss of $31,497,000 (EPS -$0.34) in the prior-year quarter. The company…
- 10-K · March 3, 2025
- Edgewise Therapeutics is a clinical-stage, muscle-focused biotech advancing two lead programs: sevasemten (EDG-5506) in multiple Phase 2 trials including the pivotal GRAND CANYON cohort and EDG-7500 in a multi-part…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EWTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever